EPCORITAMAB PLUS LENALIDOMIDE AND RITUXIMAB ACHIEVES HIGH RESPONSE RATES AND SURVIVAL BENEFITS COMPARED WITH USUAL CARE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A COMPARATIVE ANALYSIS